StockIQStockIQ.tech

Avantor, Inc. (AVTR) Stock Analysis

--

Free AI-powered analysis and research for Avantor, Inc. stock

Sector: Healthcare

AVTR snapshot

Data as of 3 Nov 2026 close. Updated daily.

Last close
15.76 USD (+0.96%)
52-week range
7.26 – 17.45
Position in range
83%
1-year change
+34.9%
Market cap (USD)
$10.7B
P/E (trailing)
32.1
RSI (14-day)
46
vs 200-day average
+40.3%
MACD
Below signal line
StockIQ score: 50/100 · Mixed signals

Avantor, Inc. scores 50/100 on StockIQ's model, which reads as mixed signals overall. The price is above its 200-day average and at 83% of its 52-week range, up 34.9% over the past year. Latest reported figures show a profit margin of 5.1%, return on equity of 5.9% and revenue growth of +4.6%.

What is driving the score
  • RSI Neutral: +5
  • Mixed Trend: +0
  • MACD Bearish: -8
  • High P/E (32.1): -10
  • Strong Long-term Uptrend: +8
  • Strong Momentum (+34.9% over 1 year): +8
  • Low Volume (0.2x): -3

Automated, general information only – not financial advice. Scores can be wrong. How the score works

Full AVTR report

Avantor, Inc. (AVTR) is listed in the Healthcare sector. The snapshot on this page updates daily; run a full report for the complete breakdown.

Analyze AVTR Now β†’

πŸ“° Latest Update

Avantor (AVTR) Stock Drops As Q3 Earnings Rebound Meets Caution

Avantor (AVTR) shares fell following the release of its Q3 earnings report, which showed a rebound in performance but included cautious guidance for future quarters. This mixed outlook raises concerns among investors about the company's ability to sustain growth amid potential market challenges. As investors weigh the implications of the cautious forecast, the stock's decline reflects uncertainty about Avantor's near-term prospects.

Read full article β†’

History

People also watch

ISRG
Intuitive Surgical Inc.
--
MRK
Merck & Co. Inc.
--
ABT
Abbott Laboratories
--
CRDF
Cardiff Oncology, Inc.
--
NGNE
Neurogene Inc.
--